Home » Newsletters » BioWorld Science

BioWorld Science

April 23, 2018

View Archived Issues

AdAlta redesigns lead candidate for idiopathic pulmonary fibrosis

Biogen and Ionis expand strategic collaboration

IMPACT 1 and IMPACT 2 trial results lead to cadazolid's discontinuation

Clementia begins MO-Ped study of palovarotene

Merck & Co. patents novel mGlu2 receptor negative allosteric modulators

Vanderbilt University describes new WDR5/MLL1 interaction inhibitors

Novel CFTR modulators divulged by Vertex Pharmaceuticals

Sichuan Kelun-Biotech Biopharmaceutical discovers new FXR agonists

EMA grants orphan drug designation for ABO-202 gene therapy program in Batten disease

First efficacy and safety data presented from the RESTORE-IMI 1 phase III trial

Daiichi Sankyo discovers novel proto-oncogene tyrosine-protein kinase receptor Ret inhibitors

Novel calpain inhibitors identified at Blade Therapeutics

Patient enrollment ongoing in phase I study of ANX-007 in primary open-angle glaucoma

Primary endpoint not met in Arpeggio study of laquinimod in primary progressive multiple sclerosis

FDA approves intravenous Akynzeo

Farnesoid X receptor agonist EYP-001 safe and well tolerated in HBV-infected patients

New phase II trial explores GS-9131 functional monotherapy in HIV-1 patients failing NRTI regimen

Fujifilm studies FF-10832 in phase I trial for advanced solid tumors

Lilly reports further data from phase III RANGE study of Cyramza in advanced urothelial carcinoma

GlaxoSmithKline presents novel hSTING agonist GSK-532

FDA clears use of Bruker Maldi Biotyper CA system to identify C. auris

Novartis files for approval of tisagenlecleucel in Japan

Fresenius decides to terminate merger agreement with Akorn

TesoRx conducts pilot study of TSD-001 for low-grade stage Ta non-muscle invasive bladder cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...